Research Site

Alfenas 37130-000

1 studies enrolling now · 4 studies all time

What they study most

Breast Cancer, Early Breast Cancer, Locally Advanced (Inoperable) or Metastatic Breast Cancer, Ophthalmic Safety in Patients With Breast Cancer

Studies at this site

• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Recruiting now
• Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) — Recruiting now
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) — Recruiting now
• An Ophthalmic Safety Study in Patients With Breast Cancer — Running, not enrolling